New prostate cancer combo study halted early
Disease control
Terminated
This study tested a new drug (exicorilant) combined with a standard treatment (enzalutamide) in 39 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to find a safe dose and check for side effects. The study was terminated early, so results…
Phase: PHASE1, PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated May 17, 2026 04:17 UTC